Zomedica Director Johnny Powers Fuels 10% Insider Buy Surge Amid Social‑Media Buzz

Insider Buying Frenzy at Zomedica Corp. The latest Form 4 shows that director Johnny D. Powers purchased an additional 100,000 shares on May 12, 2026, and a further 200,000 on May 13—all at $0.11 per share. His cumulative holding now sits at roughly 4.2 million shares, a 10 % jump from the 3.5 million shares he held after the May 8 purchase. The trade coincided with a modest 0.03 % price uptick, but the surrounding social‑media buzz was high (11.27 % above average), suggesting that investor chatter may have been riding the wave of insider activity.

What It Means for Investors Insider buying is traditionally viewed as a bullish signal, indicating confidence in a company’s near‑term prospects. For a small‑cap veterinary biopharma like Zomedica, which has a market cap of just over $100 M and a negative P/E of –3.99, any hint of insider conviction can help quell volatility. The 6.8 % weekly gain and a 124 % yearly upside reinforce a narrative that the stock is poised for a rebound. However, the price remains far below its 52‑week low ($0.035), and the company’s earnings are still negative, so caution is warranted.

Powers’ Historical Buying Pattern Powers’ previous transactions—391,129 shares on May 11 and 108,871 on May 8—show a consistent buying rhythm rather than a one‑off event. His acquisitions have always been at the same price point ($0.11), implying a systematic approach rather than opportunistic trades. The fact that he has not yet crossed the 10 % ownership threshold suggests he is building a long‑term position while staying below the regulatory trigger that would require additional disclosure. This pattern aligns with a cautious, patient investor who believes in the company’s pipeline and management team.

Industry and Company Context Zomedica operates in the niche veterinary drug space, a segment that has seen growing demand as pet owners seek higher‑quality treatments. Its recent positive price momentum, combined with insider confidence, could signal upcoming product approvals or partnership announcements. For investors, the key will be monitoring quarterly earnings for signs of revenue growth and any strategic moves that might justify the current buying trend. In the meantime, the insider activity offers a modest endorsement that could justify a modest increase in stake for value‑oriented investors.